In the latest trading session,, 1.61 million Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) shares changed hands as the company’s beta touched 1.38. With the company’s most recent per share price at $16.37 changing hands around $1.44 or 9.65% at last look, the market valuation stands at $1.85B. CNTA’s last price was a premium, traded about 6.84% off its 52-week high of $15.25. The share price had its 52-week low at $5.15, which suggests the last value was 68.54% up since then. When we look at Centessa Pharmaceuticals plc ADR’s average trading volume, we note the 10-day average is 0.46 million shares, with the 3-month average coming to 333.92K.
Analysts gave the Centessa Pharmaceuticals plc ADR (CNTA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.29. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 3 recommended CNTA as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Centessa Pharmaceuticals plc ADR’s EPS for the current quarter is expected to be -0.42.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) trade information
Instantly CNTA is in green as seen in intraday trades today. With action 21.26%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 105.65%, with the 5-day performance at 21.26% in the green. However, in the 30-day time frame, Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) is 48.28% up. Looking at the short shares, we see there were 1.1 million shares sold at short interest cover period of 3.35 days.
The consensus price target for the stock as assigned by Wall Street analysts is 15, meaning bulls need a downside of -9.13% from its recent market value. According to analyst projections, CNTA’s forecast low is 15 with 15 as the target high. To hit the forecast high, the stock’s price needs a 8.37% surge from its current level, while the stock would need to tank 8.37% for it to hit the projected low.
Centessa Pharmaceuticals plc ADR (CNTA) estimates and forecasts
Data shows that the Centessa Pharmaceuticals plc ADR share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 67.90% over the past 6 months, a -2.55% in annual growth rate that is considerably lower than the industry average of 20.20%.
The 2024 estimates are for Centessa Pharmaceuticals plc ADR earnings to increase by 0.09%.
Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.76% of Centessa Pharmaceuticals plc ADR shares while 87.94% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 89.52%. There are 87.94% institutions holding the Centessa Pharmaceuticals plc ADR stock share, with MEDICXI VENTURES MANAGEMENT (JERSEY) LTD the top institutional holder. As of 2024-06-30, the company held 19.9856% of the shares, roughly 19.96 million CNTA shares worth $180.27 million.
GENERAL ATLANTIC, L.P. holds the second largest percentage of outstanding shares, with 9.6927% or 9.68 million shares worth $87.43 million as of 2024-06-30.
